UNSPSC 51385301: Ciproquazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H18N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P8S0GE5Q4I, chemically known as 2(1h)-quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- but generally known as ciproquazone, which bears US NIH Compound Identifier 36489. European Medicines Agency schedules Ciproquazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07473MIG.

UNSPSC 51385301 Ciproquazone is a Commodity code representing pharmaceutical and medical products procured by state and local health agencies, though recent opportunities under this code tag solicitations for naloxone, generic multi-source pharmaceuticals, and over-the-counter products rather than ciproquazone specifically. State and local buyers under this code include county health departments, state HHS commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work consists of procurement of pharmaceutical supplies, including controlled substances for emergency response (naloxone for opioid overdose), generic pharmaceuticals through authorized wholesalers, and OTC products distributed to government health facilities. Issuing bodies span individual counties, state health and human services departments, and regional purchasing cooperatives that consolidate demand across multiple states and localities.

Recent activity shows solicitations from Seminole County, Florida (IFB60459723LAS, closing July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually), the Texas Health and Human Services Commission (RFI HHS0017013, posted April 3, 2026, for direct-to-manufacturer prescription program capabilities), and the Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating states including Oregon). Geographic spread includes Florida, Texas, Minnesota, and Oregon. The MMCAP solicitation is particularly large in scope, requiring vendors to maintain relationships with three authorized wholesalers and serve multiple state and local facilities across participating jurisdictions, with contracts effective July 1, 2026, and a two-year initial term. Vendors must hold compliance certifications including cGMP and DSCSA, and the code shows active procurement across diverse product lines within the pharmaceutical supply chain.